Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 12/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | PYGB | P11216 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20897004 | 1.00 | GBA1 (0.56) | GBA1MAPK1KDM4ELMNACYP2D6 | |
| SCHEMBL23906986 | 1.00 | GBA1 (0.56) | GBA1MAPK1KDM4ELMNACYP2D6 | |
| SCHEMBL13281078 | 1.00 | GBA1 (0.56) | GBA1MAPK1KDM4ELMNACYP2D6 | |
| SCHEMBL13281076 | 1.00 | GBA1 (0.56) | GBA1MAPK1KDM4ELMNACYP2D6 | |
| SCHEMBL30731536 | 0.98 | GBA1 (0.59) | GBA1MAPK1KDM4ELMNACYP2D6 | |
| SCHEMBL28491427 | 0.98 | GBA1 (0.59) | GBA1MAPK1KDM4ELMNACYP2D6 | |
| Hexane SCHEMBL28784867 | 0.98 | GBA1 (0.59) | GBA1MAPK1KDM4ELMNACYP2D6 | |
| SCHEMBL10786697 | 0.98 | GBA1 (0.59) | GBA1MAPK1KDM4ELMNACYP2D6 | |
| SCHEMBL23787746 | 0.98 | GBA1 (0.59) | GBA1MAPK1KDM4ELMNACYP2D6 | |
| SCHEMBL29120516 | 0.98 | GBA1 (0.59) | GBA1MAPK1KDM4ELMNACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1460085-A1 | Genes and proteins for the biosynthesis of the glycopeptide antibiotic teicoplanin | Vicuron Pharmaceuticals, Inc. (US) | 2004-09-22 | — | — | EP | claimed |
| EP-1735337-B2 | METHOD OF PRODUCING HIGHLY PURE TEICOPLANIN | DONG KOOK PHARM CO LTD (KR) | 2013-04-10 | — | — | EP | disclosed |
| EP-1735337-B1 | METHOD OF PRODUCING HIGHLY PURE TEICOPLANIN | DONG KOOK PHARM CO LTD (KR) | 2009-08-19 | — | — | EP | disclosed |
| US-7192743-B2 | Method of producing teicoplanin | DONG KOOK PHARMACEUTICAL CO., LTD. (KR) | 2007-03-20 | — | — | US | disclosed |
| EP-1735337-A1 | METHOD OF PRODUCING HIGHLY PURE TEICOPLANIN | Dong Kook Pharmaceutical Co., Ltd. (KR) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005116059-A1 | METHOD OF PRODUCING HIGHLY PURE TEICOPLANIN | DONG KOOK PHARMACEUTICAL CO., LTD. (KR) | 2005-12-08 | — | — | WO | disclosed |
| US-20050245481-A1 | applying solutions comprising culture broths containing teicoplanin, from Actinoplanes teichomyceticus strains capable of producing teicoplanin, to porous adsorption resins, then eluting, treating with activated carbon to recover the teicoplanin andultrafiltration; purification | DONG KOOK PHARMACEUTICAL CO., LTD. (KR) | 2005-11-03 | — | — | US | disclosed |
| EP-1460085-A1 | Genes and proteins for the biosynthesis of the glycopeptide antibiotic teicoplanin | Vicuron Pharmaceuticals, Inc. (US) | 2004-09-22 | — | — | EP | disclosed |
| US-5936074-A | REACTING TEICOPLANIN WITH ECHINOCANDIN BETA DEACYLASE, THEN FORMING SALT AND/OR DEPROTECTING AMINO GROUP; BACTERICIDES AGAINST GRAM-POSITIVE BACTERIA | ELI LILLY AND COMPANY (US) | 1999-08-10 | — | — | US | disclosed |
| EP-0873996-A1 | Process of deacylation of teicoplanin and product thereby obtained | ELI LILLY AND COMPANY (US) | 1998-10-28 | — | — | EP | disclosed |